Last reviewed · How we verify
SULFACETAMIDE SODIUM
SULFACETAMIDE SODIUM is a drug. It is currently FDA-approved (first approved 1961).
Sulfacetamide sodium is used to treat Meibomian Gland Dysfunction. It is administered through intraductal meibomian gland probing, a procedure that involves probing the meibomian glands.
At a glance
| Generic name | SULFACETAMIDE SODIUM |
|---|---|
| Modality | Small molecule |
| Phase | FDA-approved |
| First approval | 1961 |
Approved indications
Common side effects
- Stevens-Johnson syndrome
- Local hypersensitivity
- Systemic lupus erythematosus
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SULFACETAMIDE SODIUM CI brief — competitive landscape report
- SULFACETAMIDE SODIUM updates RSS · CI watch RSS
Frequently asked questions about SULFACETAMIDE SODIUM
What is SULFACETAMIDE SODIUM?
SULFACETAMIDE SODIUM is a Small molecule drug.
When was SULFACETAMIDE SODIUM approved?
SULFACETAMIDE SODIUM was first approved on 1961.
What development phase is SULFACETAMIDE SODIUM in?
SULFACETAMIDE SODIUM is FDA-approved (marketed).
What are the side effects of SULFACETAMIDE SODIUM?
Common side effects of SULFACETAMIDE SODIUM include Stevens-Johnson syndrome, Local hypersensitivity, Systemic lupus erythematosus.
Related
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing